|COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring.|
Human T cell immunity against tumour antigens
If you have a question about this talk, please contact Prof. Jim Kaufman.
Host: Peter Goon (email@example.com)
My group studies human T cells and their potential role in therapy of pre-malignant and malignant diseases. Our main focus has been on human papillomaviruses (HPV) that are associated with the development of cervical cancer. We developed techniques to study HPV specific T cells responses for a series of phase I/II trials with a candidate therapeutic vaccine (TA-HPV). We demonstrated that systemic T cell responses against HPV were relatively weak, both in vaccinated and non-vaccinated patients. Nevertheless we could isolate and grow T cell clones from rare populations, that could kill cancer cells in vitro. This suggests a therapeutic potential for HPV specific T cells but new approaches will be required to induce large numbers of efficacious T cells. We are currently defining new T cell targets based on proteins that are abnormally expressed in cancer. These targets may be applicable to a broad range of human cancers, particularly those caused by oncogenic viruses.
This talk is part of the Immunology in Pathology series.
This talk is included in these lists:
Note that ex-directory lists are not shown.
Other listsNew Thinking In Economics 'Love and Revolution' reading group cambridge advanced imaging
Other talksJill Lepore: The Rise and Fall of the Fact From bench to bedside: the perilous journey of drug discovery Kv10.1: a potassium channel involved in malignant growth What Is Supreme about the Supreme Council of Kenya Muslims (SUPKEM)? Challenging the practices of representativeness amongst Muslims in Kenya Data Science for the World of Moving Things Modular invariants for group-theoretical modular data